Literature DB >> 29559753

Clinical Evaluation of Measuring the ACT during Elective Cardiac Surgery with Two Different Devices.

Florian Falter1, Nabeel Razzaq2, Martin John1, Jens Fassl3, Markus Maurer3, Sean Ewing4, Ross Hofmeyr4.   

Abstract

Unfractionated heparin is the mainstay of anticoagulation during cardiac surgery on cardiopulmonary bypass (CPB) due to its low cost, quick onset, and ease of reversal. Since over 30 years, the activated clotting time (ACT) has been used to assess the level of heparin activity both before and after CPB. We compared two different methods of measuring the ACT: i-STAT, which uses amperometric detection of thrombin cleavage, and Hemochron Jr, which is based on detecting viscoelastic changes in blood. We included 402 patients from three institutions (Papworth Hospital, Cambridge, UK; Groote Schuur, Cape Town, South Africa; University Hospital Basel, Basel, Switzerland) undergoing elective cardiac surgery on CPB in our study. We analyzed duplicate samples on both devices at all standard measuring points during the procedure. The correlation coefficient between two Hemochron and two i-STAT devices was .9165 and .9857, respectively. The within-subject coefficient of variation (WSCV) ranged from 8.2 to 13.6% for the Hemochron and from 4.1 to 9.1% for the i-STAT. We found that the number of occasions where one of the duplicate readings was >1,000 seconds while the other was below or close to the clinically significant threshold of 400 seconds were higher for the Hemochron. We found the i-STAT to systematically return higher measurements. We conclude that the i-STAT provides a more reliable test for heparin activity and assesses safe anticoagulation during cardiac surgery on pump. The fact the that the i-STAT reads higher than the Hemochron leads to the recommendation to validate the methods against each other before changing devices.

Entities:  

Keywords:  activated clotting time (ACT); anticoagulation; cardiopulmonary bypass; method comparison

Mesh:

Substances:

Year:  2018        PMID: 29559753      PMCID: PMC5848083     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  18 in total

1.  Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer.

Authors:  J A Young; C T Kisker; D B Doty
Journal:  Ann Thorac Surg       Date:  1978-09       Impact factor: 4.330

2.  Comparison of the i-STAT handheld activated clotting time with the Hemochron activated clotting time during and after percutaneous coronary intervention.

Authors:  Jeffrey M Schussler; James J Aguanno; Elizabeth N Glover; Nancy A Vish; Laurie A Wissinger; John R Schumacher; Kevin R Wheelan
Journal:  Am J Cardiol       Date:  2003-02-15       Impact factor: 2.778

3.  Validation of the i-STAT handheld activated clotting time for use with bivalirudin.

Authors:  Jeffrey M Schussler; Stuart R Lander; Laurie A Wissinger; Azam Anwar; Michael S Donsky; Kenneth B Johnson; Ravi C Vallabhan; Jason B Wischmeyer
Journal:  Am J Cardiol       Date:  2004-05-15       Impact factor: 2.778

4.  Comparison of point-of-care activated clotting time systems utilized in a single pediatric institution.

Authors:  Jorge W Ojito; Robert L Hannan; Michelle Moore Burgos; Hyunsoo Lim; Monique Huynh; Evelio Velis; Marino Arocha; Christopher F Tirotta; Redmond P Burke
Journal:  J Extra Corpor Technol       Date:  2012-03

5.  Inhibition of thrombocyte aggregation during extracorporeal lung assist: a case report.

Authors:  Alois Philipp; Thomas Müller; Thomas Bein; Maik Foltan; Franz-Xaver Schmid; Dietrich Birnbaum; Christof Schmid
Journal:  Perfusion       Date:  2007-07       Impact factor: 1.972

Review 6.  Serious anaphylactic reactions due to protamine sulfate: a systematic literature review.

Authors:  Mads Nybo; Jonna Skov Madsen
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-08       Impact factor: 4.080

7.  Clinical evaluation of the i-STAT kaolin activated clotting time (ACT) test in different clinical settings in a large academic urban medical center: comparison with the Medtronic ACT Plus.

Authors:  Elizabeth Lee Lewandrowski; Elizabeth M Van Cott; Kimberly Gregory; Ik-Kyung Jang; Kent B Lewandrowski
Journal:  Am J Clin Pathol       Date:  2011-05       Impact factor: 2.493

8.  Pump Priming Practices and Anticoagulation in Cardiac Surgery: Results From the Global Cardiopulmonary Bypass Survey.

Authors:  Lachlan F Miles; Timothy G Coulson; Carlos Galhardo; Florian Falter
Journal:  Anesth Analg       Date:  2017-12       Impact factor: 5.108

Review 9.  Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin.

Authors:  Sarah A Spinler; Ann K Wittkowsky; Edith A Nutescu; Maureen A Smythe
Journal:  Ann Pharmacother       Date:  2005-06-14       Impact factor: 3.154

10.  Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.

Authors:  T Mochizuki; P J Olson; F Szlam; J G Ramsay; J H Levy
Journal:  Anesth Analg       Date:  1998-10       Impact factor: 5.108

View more
  4 in total

Review 1.  Are We Able to Dose Protamine Accurately Yet? A Review of the Protamine Conundrum.

Authors:  Patrick Hecht; Martin Besser; Florian Falter
Journal:  J Extra Corpor Technol       Date:  2020-03

2.  Point-of-Care Measurement of Kaolin Activated Clotting Time during Cardiopulmonary Bypass: A Single Sample Comparison between ACT Plus and i-STAT.

Authors:  Nousjka P A Vranken; Amber J A J Theelen; Tamar Orbons; Paul J C Barenbrug; Patrick W Weerwind
Journal:  J Extra Corpor Technol       Date:  2021-03

3.  Accuracy of point-of-care coagulation testing during cardiopulmonary bypass in a patient post COVID-19 infection.

Authors:  Nimrat Grewal; David Yousef; Meindert Palmen; Robert Klautz; Jeroen Eikenboom; Jeroen Wink
Journal:  J Cardiothorac Surg       Date:  2022-05-07       Impact factor: 1.522

4.  Point-of-care measurement of activated clotting time for cardiac surgery as measured by the Hemochron signature elite and the Abbott i-STAT: agreement, concordance, and clinical reliability.

Authors:  Daniel Dirkmann; Elisabeth Nagy; Martin W Britten; Jürgen Peters
Journal:  BMC Anesthesiol       Date:  2019-09-06       Impact factor: 2.217

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.